Otsuka Backs Up Tolvaptan Data In Polycystic Kidney Disease
Further top-line results from a Phase III study have been promising, and the US FDA will have to decide if the previously rejected polycystic kidney additional indication for tolvaptan is now firmly supported by safety and efficacy data.
You may also be interested in...
The latest US drug development news and highlights from our Performance Tracker.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.